Olema Pharmaceuticals Inc
OLMA27.450USD
-0.220-0.80%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.88BMarket Cap
LossP/E TTM
More Details of Olema Pharmaceuticals Inc Company
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. It is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.
Olema Pharmaceuticals Inc Info
Ticker SymbolOLMA
Company nameOlema Pharmaceuticals Inc
IPO dateNov 19, 2020
CEOBohen (Sean P)
Number of employees96
Security typeOrdinary Share
Fiscal year-endNov 19
Address780 Brannan Street
CitySAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94103
Phone14156513316
Websitehttps://olema.com/
Ticker SymbolOLMA
IPO dateNov 19, 2020
CEOBohen (Sean P)
Company Executives of Olema Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. David C. Myles, Ph.D.
Mr. David C. Myles, Ph.D.
Chief Discovery and Non-Clinical Development Officer
Chief Discovery and Non-Clinical Development Officer
586.38K
+4.02%
Mr. Andrew Rappaport
Mr. Andrew Rappaport
Independent Director
Independent Director
385.96K
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
83.88K
--
Ms. Shawnte M. Mitchell
Ms. Shawnte M. Mitchell
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Graham L. Walmsley, M.D., Ph.D.
Dr. Graham L. Walmsley, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Naseem Zojwalla, M.D.
Dr. Naseem Zojwalla, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ian Clark
Mr. Ian Clark
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Sean P. Bohen, M.D., Ph.D.
Mr. Sean P. Bohen, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Shane Kovacs
Mr. Shane Kovacs
Chief Operating and Financial Officer
Chief Operating and Financial Officer
--
--
Dr. Gorjan Hrustanovic, Ph.D.
Dr. Gorjan Hrustanovic, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. David C. Myles, Ph.D.
Mr. David C. Myles, Ph.D.
Chief Discovery and Non-Clinical Development Officer
Chief Discovery and Non-Clinical Development Officer
586.38K
+4.02%
Mr. Andrew Rappaport
Mr. Andrew Rappaport
Independent Director
Independent Director
385.96K
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
83.88K
--
Ms. Shawnte M. Mitchell
Ms. Shawnte M. Mitchell
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Graham L. Walmsley, M.D., Ph.D.
Dr. Graham L. Walmsley, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Naseem Zojwalla, M.D.
Dr. Naseem Zojwalla, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bain Capital Life Sciences Investors, LLC
8.70%
Paradigm BioCapital Advisors LP
8.64%
BVF Partners L.P.
6.73%
BlackRock Institutional Trust Company, N.A.
5.01%
Janus Henderson Investors
4.56%
Other
66.36%
Shareholders
Shareholders
Proportion
Bain Capital Life Sciences Investors, LLC
8.70%
Paradigm BioCapital Advisors LP
8.64%
BVF Partners L.P.
6.73%
BlackRock Institutional Trust Company, N.A.
5.01%
Janus Henderson Investors
4.56%
Other
66.36%
Shareholder Types
Shareholders
Proportion
Hedge Fund
29.57%
Investment Advisor
26.41%
Investment Advisor/Hedge Fund
20.78%
Venture Capital
8.45%
Research Firm
4.02%
Individual Investor
3.23%
Bank and Trust
0.09%
Insurance Company
0.03%
Pension Fund
0.02%
Other
7.41%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
315
72.32M
105.37%
-10.03M
2025Q2
320
70.59M
103.16%
-12.18M
2025Q1
327
72.74M
106.44%
-11.08M
2024Q4
313
78.82M
113.63%
+3.60M
2024Q3
301
63.64M
110.87%
-10.05M
2024Q2
299
62.60M
111.72%
-7.29M
2024Q1
288
60.06M
107.83%
-1.82M
2023Q4
271
55.06M
100.31%
-2.15M
2023Q3
263
50.27M
92.75%
-945.85K
2023Q2
259
39.52M
96.98%
-9.43M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bain Capital Life Sciences Investors, LLC
6.84M
9.97%
--
--
Jun 30, 2025
Paradigm BioCapital Advisors LP
6.76M
9.86%
+23.00K
+0.34%
Jun 30, 2025
BVF Partners L.P.
5.30M
7.72%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.96M
5.77%
+637.23K
+19.20%
Jun 30, 2025
Janus Henderson Investors
3.02M
4.4%
+3.02M
--
Jun 30, 2025
Deep Track Capital LP
3.44M
5.02%
--
--
Jun 30, 2025
Logos Global Management LP
3.21M
4.68%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
3.27M
4.76%
+395.39K
+13.77%
Jun 30, 2025
Franklin Advisers, Inc.
3.01M
4.39%
--
--
Jun 30, 2025
Woodline Partners LP
3.51M
5.11%
+2.03M
+137.22%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
1.5%
ALPS Medical Breakthroughs ETF
0.25%
iShares Micro-Cap ETF
0.1%
Invesco Nasdaq Biotechnology ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.06%
iShares Health Innovation Active ETF
0.06%
iShares Biotechnology ETF
0.04%
iShares Russell 2000 Value ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
Avantis US Small Cap Equity ETF
0.03%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.5%
ALPS Medical Breakthroughs ETF
Proportion0.25%
iShares Micro-Cap ETF
Proportion0.1%
Invesco Nasdaq Biotechnology ETF
Proportion0.06%
ProShares Ultra Nasdaq Biotechnology
Proportion0.06%
iShares Health Innovation Active ETF
Proportion0.06%
iShares Biotechnology ETF
Proportion0.04%
iShares Russell 2000 Value ETF
Proportion0.04%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.03%
Avantis US Small Cap Equity ETF
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Olema Pharmaceuticals Inc?
The top five shareholders of Olema Pharmaceuticals Inc are:
Bain Capital Life Sciences Investors, LLC holds 6.84M shares, accounting for 9.97% of the total shares.
Paradigm BioCapital Advisors LP holds 6.76M shares, accounting for 9.86% of the total shares.
BVF Partners L.P. holds 5.30M shares, accounting for 7.72% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.96M shares, accounting for 5.77% of the total shares.
Janus Henderson Investors holds 3.02M shares, accounting for 4.40% of the total shares.
Bain Capital Life Sciences Investors, LLC holds 6.84M shares, accounting for 9.97% of the total shares.
Paradigm BioCapital Advisors LP holds 6.76M shares, accounting for 9.86% of the total shares.
BVF Partners L.P. holds 5.30M shares, accounting for 7.72% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.96M shares, accounting for 5.77% of the total shares.
Janus Henderson Investors holds 3.02M shares, accounting for 4.40% of the total shares.
What are the top three shareholder types of Olema Pharmaceuticals Inc?
The top three shareholder types of Olema Pharmaceuticals Inc are:
Bain Capital Life Sciences Investors, LLC
Paradigm BioCapital Advisors LP
BVF Partners L.P.
Bain Capital Life Sciences Investors, LLC
Paradigm BioCapital Advisors LP
BVF Partners L.P.
How many institutions hold shares of Olema Pharmaceuticals Inc (OLMA)?
As of 2025Q3, 315 institutions hold shares of Olema Pharmaceuticals Inc, with a combined market value of approximately 72.32M, accounting for 105.37% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 2.20%.
What is the biggest source of revenue for Olema Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for Olema Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
